Spots Global Cancer Trial Database for Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Official Title: Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Study ID: NCT01891968

Conditions

Leukemia

Interventions

Bortezomib

Study Description

Brief Summary: The goal of this clinical research study is to learn if bortezomib can help to control MDS. The safety of this drug will also be studied. Bortezomib is designed to block a protein that causes cells to grow. This may cause cancer cells to die.

Detailed Description: Study Drug Administration: If you are found to be eligible to take part in this study, you will receive bortezomib as an injection under the skin on Days 1, 4, 8, and 11 of each 21-day cycle. Study Visits: At each visit, you will be asked about any drugs you may be taking and any side effects you may be having. One (1) time a week during Cycle 1, blood (about 2 tablespoons) will be drawn for routine tests. On Day 21 of Cycles 1 and 3, you will have a bone marrow aspiration and/or biopsy to check the status of the disease and for cytogenetic testing. On Day 1 of Cycles 2 and beyond, blood (about 2 tablespoons) will be drawn for routine tests. If your doctor thinks it is needed, you may have additional bone aspirations and/or biopsies to check the status of the disease and/or for cytogenetic testing. Length of Treatment: You may continue taking the study drug for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, if you are able to have an allogeneic stem cell transplant (a stem cell transplant from a donor), or if you are unable to follow study directions. Your participation on the study will be over once you have completed the end-of- treatment visit. End-of-Treatment Visit: At 30 days after your last dose of study drug: * You will be asked about any drugs you may be taking and any side effects you may have had. * Blood (about 2 tablespoons) will be drawn for routine tests. * If your doctor thinks it is needed, you will have a bone marrow aspirate and/or biopsy to check the status of the disease and for cytogenetic testing. This is an investigational study. Bortezomib is FDA approved and commercially available to treat multiple myeloma and mantle cell lymphoma. Giving it to patients with MDS is investigational. Up to 40 participants will be enrolled in this study. All will take part at MD Anderson.